NCT00617994View on ClinicalTrials.gov

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions

Psoriasis

Interventions

DRUG

Ruxolitinib

Ruxolitinib 1.5% cream BID for 28 days

Trial Locations (4)

14623

Rochester

55432

Fridley

77840

College Station

78759

Austin

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY

NCT00617994 - Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis | Biotech Hunter | Biotech Hunter